Atractylenolide II

• CAT Number: I004721
• CAS Number: 73069-14-4
• Molecular Formula: C15H20O2
• Molecular Weight: 232.32
• Purity: ≥95%
• Target: anticancer natural compound
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 82.3 μM(B16 melanoma cell, 48 h) [1]

Atractylenolide II(CAT: I004721), a sesquiterpene compound derived from Atractylodes macrocephala, exhibits anti-proliferative activity and holds potential as an anticancer natural compound. In vitro, studies have demonstrated that Atractylenolide II inhibits cell proliferation in a dose-dependent manner, with an IC50 value of 82.3 μM in B16 melanoma cells. It induces G1 phase cell cycle arrest and apoptosis, accompanied by modulation of various signaling molecules involved in cell cycle regulation and apoptosis, including Cdk2, Akt, ERK, p38, p53, p21, p27, and caspases. Notably, the growth inhibitory and apoptotic effects of Atractylenolide II are attenuated by the inhibition of p53. Furthermore, Atractylenolide II reduces the expression levels of phosphor-STAT3, phospho-Src, Mcl-1, and Bcl-xL, and its antiproliferative and apoptotic effects are diminished by the overexpression of a constitutively active variant of STAT3 (STAT3C) in cancer cells. In vivo, studies using a B16 xenograft mouse model have shown that daily administration of Atractylenolide II inhibits tumor growth and suppresses the activation/phosphorylation of STAT3 and Src in the xenografts.

Reference

[1]. Ye Y, et al. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol. 2011 Jun 14;136(1):279-82.

[2]. Fu XQ, et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol. 2014 Nov;23(11):855-7.